Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Benzthiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 13/20 | 0.41 |
| ▸ | CA2 | P00918 | 12/20 | 0.41 |
| ▸ | CA12 | O43570 | 11/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzthiazide SCHEMBL26257 | 0.95 | ALDH1A1 (0.63) | ALDH1A1CYP3A4CYP2C9KDM4ETSHR | |
| Benzthiazide SCHEMBL1276519 | 0.94 | ALDH1A1 (0.60) | ALDH1A1CYP3A4CYP2C9KDM4ETSHR | |
| Benzthiazide SCHEMBL345215 | 0.94 | ALDH1A1 (0.62) | ALDH1A1CYP3A4CYP2C9KDM4ETSHR | |
| Benzthiazide SCHEMBL9517821 | 0.94 | ALDH1A1 (0.62) | ALDH1A1CYP3A4CYP2C9KDM4ETSHR | |
| Benzthiazide SCHEMBL7217920 | 0.94 | ALDH1A1 (0.62) | ALDH1A1CYP3A4CYP2C9KDM4ETSHR | |
| Benzthiazide SCHEMBL7102453 | 0.94 | ALDH1A1 (0.62) | ALDH1A1CYP3A4CYP2C9KDM4ETSHR | |
| Benzthiazide SCHEMBL6546528 | 0.94 | ALDH1A1 (0.62) | ALDH1A1CYP3A4CYP2C9KDM4ETSHR | |
| Benzthiazide SCHEMBL23860715 | 0.93 | ALDH1A1 (0.58) | ALDH1A1CYP3A4CYP2C9KDM4ETSHR | |
| Benzthiazide SCHEMBL386685 | 0.93 | ALDH1A1 (0.58) | ALDH1A1CYP3A4CYP2C9KDM4ETSHR | |
| Benzthiazide SCHEMBL2376967 | 0.93 | ALDH1A1 (0.58) | ALDH1A1CYP3A4CYP2C9KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670270-B2 | Minicell based delivery of biologically active compounds | VAXIION THERAPEUTICS, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150218254-A1 | MINICELL BASED DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | VAXIION THERAPEUTICS, LLC | 2015-08-06 | — | — | US | disclosed |
| EP-2272946-B9 | Minicell compositions and methods | VAXIION THERAPEUTICS LLC (US) | 2015-06-24 | — | — | EP | disclosed |
| US-9017986-B2 | Minicell based delivery of biologically active compounds | VAXIION THERAPEUTICS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2272946-B1 | Minicell compositions and methods | VAXIION THERAPEUTICS INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20130337545-A1 | MINICELL BASED DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | VAXIION THERAPEUTICS, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20120142079-A1 | MINICELL BASED DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | VAXIION THERAPEUTICS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120135503-A1 | MINICELL BASED DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | VAXIION THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8101396-B2 | Minicells displaying antibodies or derivatives thereof and comprising biologically active compounds | VAXIION THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2390308-A1 | Minicell compositions and methods | Vaxiion Therapeutics Inc (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20030199088-A1 | For the production of achromosomal archeabacterial, eubacterial and anucleate eukaryotic cells; for therapeutics, diagnostics, drug discovery, proteomics | VAXIION THERAPEUTICS, LLC | 2003-10-23 | — | — | US | disclosed |
| US-20030199005-A1 | Production of achromosomal and anucleate cells for diagnositic and therapeutic uses, as well as research tools and agents for drug discovery | MPEX BIOSCIENCES, INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030194714-A1 | Minicell-based transformation | MPEX BIOSCIENCES, INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030194798-A1 | For diagnositic, therapeutic, research, and drug discovery applications | MPEX BIOSCIENCES, INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030190749-A1 | Expression element that comprises a gene linked to sequences that are inducible and/or repressible; mutations; useful in diagnositics, therapeutics and drug discovery | MPEX BIOSCIENCES, INC. | 2003-10-09 | — | — | US | disclosed |
| US-20030190601-A1 | Useful for diagnosis and therapy, research tools for drug discovery | MPEX BIOSCIENCES, INC. | 2003-10-09 | — | — | US | disclosed |
| US-20030190683-A1 | Production of achromosomal and anucleate cells useful for diagnositic and therapeutic uses, as well as research tools and agents for drug discovery | MPEX BIOSCIENCES, INC. | 2003-10-09 | — | — | US | disclosed |
| US-20030166099-A1 | Minicells comprising membrane proteins | MPEX BIOSCIENCES, INC. | 2003-09-04 | — | — | US | disclosed |
| US-20030166279-A1 | Cell culture incubation and transferring nucleic acid from a minicell to a cell; diagnositic and therapeutic uses, as research tools and agents for drug discovery screening | MPEX BIOSCIENCES, INC. | 2003-09-04 | — | — | US | disclosed |
| WO-2003072014-A2 | MINICELL COMPOSITIONS AND METHODS | MPEX BIOSCIENCE, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218254-A1 | MINICELL BASED DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | PCNA, PAICS, TOP1 | ALDH1A1 4535/4885CYP3A4 4829/4885CYP2C9 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.